BioCryst to receive royalties from cancer treatment approved in Japan

Durham-based BioCryst Pharmaceuticals (Nasdaq: BCRX) stands to receive royalties from a new cancer therapy approved in Japan. The company announced that Mundipharma – with which it has a sub-licensing agreement – has received approval from the the Ministry of Health, Labor and Welfare in Japan for Mundesine, a therapy for the treatment of Peripheral T-Cell Lymphoma. “Under the terms of the agreement with Mundiphar ma, BioCryst will receive tiered royalties ranging from the mid- to high-single…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news

Related Links:

High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study, Published online: 13 August 2018; doi:10.1038/s41409-018-0294-2High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
Purpose of review To describe the relevance of CD47 in the tumor microenvironment and summarize data on anti-CD47 therapies, including its role in cutaneous T-cell lymphoma (CTCL). Recent findings CD47 is expressed on all normal cells and targets SIRPα on the surface of myeloid cells. However, CD47 is found to be overexpressed on cancer cells. CD47–SIRPα interaction inhibits macrophage phagocytosis, allowing cancer cells to escape immune surveillance. Current focus in immunotherapy has been targeted toward inhibiting CD47–SIRPα interaction via anti-CD47 antibodies. This activates innate i...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: INNOVATIVE AGENTS AND TREATMENT MODALITIES: Edited by Ahmad Awada and Steven T. Rosen Source Type: research
AbstractAngioimmunoblastic T-cell lymphoma (AITL) is a subtype of peripheral T-cell lymphoma with a poor prognosis: the 5-year survival rate is approximately 30%. Somatic driver mutations have been found inTET2, IDH2, DNMT3A, RHOA, FYN, PLCG1, andCD28, whereas germline susceptibility to AITL has to our knowledge not been studied. The homogenous Finnish population is well suited for studies on genetic predisposition. Here, we performed an exome-wide rare variant analysis in 23 AITL patients. No germline mutations were found in the driver genes, implying that they are not frequently involved in genetic AITL predisposition. P...
Source: Familial Cancer - Category: Cancer & Oncology Source Type: research
AbstractThe inhibition of histone deacetylase (HDAC) has become a well-recognized target for cancer therapy. Until now only five HDAC inhibitors i.e., SAHA, romidepsin (FK-228), belinostat, chidamide, and panobinostat have been approved by FDA. The first four of them are being employed for the treatment of cutaneous T-cell lymphoma and last one is being used for the treatment of multiple myeloma. In the present study, structure and ligand-based computational approaches were selected to design novel histone deacetylase inhibitors. A ligand-based pharmacophore model was developed employing phase module that exhibited five si...
Source: Medicinal Chemistry Research - Category: Chemistry Source Type: research
Background: Canadian analyses from the last few decades have shown that the incidence of CTCL has been increasing until 1998 and then it has stabilized at the rate of ∼11-12 cases per million individuals per year. Furthermore, our recent comprehensive investigations on CTCL epidemiology in Canada have documented a nonrandom distribution of this cancer in Canada with higher CTCL incidences being detected in Newfoundland and Labrador, Maritime, and Prairie provin ces. Geographic CTCL clustering of cases was observed in a number of specific industrial communities throughout Canada.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Genomic instability is a hallmark of cancer, and an enabling factor for the genetic alterations that drive cancer development and progression. Many cancers including cutaneous T-cell lymphomas (CTCL) exhibit an aggressive form of genomic instability known as chromosomal instability, in which gross chromosomal aberrations are abundant. The ectopic expression of germ cell proteins (i.e., cancer/testis antigens), has been suggested as a mechanism through which chromosomal instability may arise in cancers via aberrant activation of germline processes which induce DNA double strand breaks and chromosomal rearrangements.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Background: Primary cutaneous peripheral T-cell lymphoma, unspecified (PCPTL) accounts for less than 6% of cutaneous T-cell lymphoma cases. No large study in literature has thus far analyzed survival of PCPTL patients. We aim to evaluate the overall survival (OS) of PCPTL patients stratified by the primary disease site.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Introduction: Mycosis fungoides (MF) and lymphomatoid papulosis (LyP) are classified into the primary cutaneous T-cell lymphomas (CTCL) group according to the European Organization for Research and Treatment of Cancer (EORTC) and World Health Organization (WHO) classification (fourth edition, 2008). Both entities are considered different, with distinctive clinical, histopathologic, immunophenotypic, and molecular features.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Background: Primary cutaneous CD30+ lymphoproliferative disorders (PCLPD), the second most common type of primary cutaneous T-cell lymphomas, account for ∼25%-30% of the cases. Only small retrospective studies exist in the literature, and it remains unclear if patients from different racial groups have different survival outcomes.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Abstract Suberoylanilide hydroxamic acid (SAHA) is a potent small molecule pan-inhibitor of histone deacetylases (HDACi) approved for treatment of Cutaneous T-cell Lymphoma (CTCL). However, SAHA exhibits poor selectivity for cancer cells over non-cancer cells. Towards improving its selectivity for cancer cells, we exemplify a novel SAHA prodrug (SAHA-OBP) that gets activated in the presence of H2O2, a reactive oxygen species (ROS) known to be overexpressed in cancer cells. The high endogenous ROS content in cancer cells triggers rapid removal of the OBP cap to release active SAHA. The SAHA-OBP prodrug demonstrates...
Source: ChemMedChem - Category: Chemistry Authors: Tags: ChemMedChem Source Type: research
More News: American Health | Cancer | Cancer & Oncology | Cancer Therapy | Health Management | Lymphoma | T-cell Lymphoma